Atherosclerosis International Meeting
7- 9 September 2018
Chalkidiki, Greece

Friday, 7 September 2018

11.00-11.45 Registrations

11.45-12.00 Introduction – Welcome Messages
L. Tokgozoglu
V. Kotsis

Atherosclerosis and cardiovascular risk update
Chair: A. Tselepis, D. Ural

12.00-12.30 Many faces of atherosclerotic vascular damage. N. Koylan

12.30-13.00 Imaging and Biomarkers: Are they really helpful? N. Ozer

13.00-13.30 How do we determine risk in 2018? Z. Ongen

13.30-14.30 Light Lunch
Clinical workshop

14.30-15.30  Case presentations from the Turkish Cardiology Society.
Chair: L. Tokgozoglu, M. Elisaf
Interactive discussion with participants (4 cases 10 min each, followed by 5 min discussion)

CVD epidemiology and prevention
Chair: V Athyros, M. Kayikcioglu


16.00-16.30  Precision medicine in 2018 or What is new in prevention? D. Ural

16.30-16.45  Coffee Break

Cardiovascular risk beyond LDL
Chair: C. Savopoulos, N. Koylan

16.45-17.15  How important is non-HDL? L. Tokgozoglu

17.15-17.45  Lp(a). Present and future. A. Tselepis
17.45-18.15 Nonalcoholic steatohepatitis: the emerging cardiovascular risk factor. V. G. Athyros

**Dyslipidemias. New treatment options**
Chair: D. Panagiotakos, N. Ozer

18.15-18.45 PCSK9 inhibitors in patients with familial hypercholesterolemia.
M. Elisaf

18.45-19.15 How should we manage patients with high triglycerides?
M. Kayikcioglu

**Saturday, 8 September 2018**

**Treatment options and update on statin treatment**
Chair. Kotsis V, M. Kayikcioglu

09.00-09.30 How far should we lower LDL? H. Kultursay

09.30-10.00 How should we treat patients with type II diabetes and dyslipidemia.
E. Liberopoulos

10.00-10.30 Statins, where are we? V. Sansoy
10.30-11.00  Statin intolerance. K. Tziomalos

11.00-11.30  Coffee Break

11.30-12.00  Distinguished Lecture
Chair. A. Tselepis
Shared risk factors for cardiovascular disease and dementia – genetic, epidemiologic, and causal aspects. R. Frikke-Schmidt

Clinical workshop
12.00-13.00  Case presentations from the Hellenic Atherosclerosis Society.
Chair: Liberopoulos E, V. Sansoy
Interactive discussion with participants (5 cases 10 min each). (4 cases 10 min each followed by 5 min discussion)

Treatment within co-morbidities: obesity, type II diabetes, hypertension and stroke
Chair. K Tziomalos, Z. Ongen

V. Kotsis

13.30-14.00  Treatment of diabetes in obesity. N. Katsiki

14.00-14.30  Treatment of hypertension and dyslipidemia after acute stroke.
X. Savopoulous
Sunday, 9 September 2018

Case report presentation

09.00-09.30  09.30-10.00 Patient with hypertension and dyslipidemia. V. Kotsis

10.00-10.30  Patient with CAD and LDLc 85 on atorvaatatin. M. Kayikcioglu

10.30-11.00  Obese Patient with a stable angina and Tgs 210 mg/dL. K. Tziomalos

11.00-11.30  Patient without treatment with obesity and LDL 210. V. Athyros

11.30-12.00  Patient with hypertension, diabetes and LDL 145 mg/dL. N. Katsiki

12.00-12.30  Patient with LDL 300mg/dL and family history of early CAD. L. Tolozoglu